Abbvie Inc. Common Stock (ABBV) 71.36 $ABBV
AbbVie (ABBV) Stock Price Target Raised at Deutsche Bank
at The Street - 53 mins ago
AbbVie (ABBV) price target was increased to $85 from $80 at Deutsche Bank, while reiterating its 'buy' rating.
ABBV: 71.36 (+0.13)
Gilead (GILD) Beats on Q2 Earnings, Raises 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 33 mins ago
Gilead Sciences, Inc.'s (GILD) second-quarter earnings (including stock-based compensation expenses) of $3.10 per share surpassed the Zacks Consensus Estimate of $2.83.
GILD: 117.00 (+3.93), LGND: 102.51 (-3.33), ABBV: 71.36 (+0.13), ANAC: 147.03 (-4.28)
Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 338.10 (-1.40), BIIB: 311.50 (-8.43), SHPG: 267.25 (+4.00), MYL: 57.07 (+0.72), AMGN: 172.11 (-0.63), ABBV: 71.36 (+0.13), TEVA: 71.22 (-0.19)
The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts
ESRX: 92.20 (-0.18), GILD: 117.00 (+3.93), ACHN: 8.40 (-0.01), MRK: 58.66 (+1.14), ABBV: 71.36 (+0.13)
Avoid Gilead Shares for Now
at The Street - Tue Jul 28, 7:00AM CDT
Competition and lower earnings cloud its future.
GILD: 117.00 (+3.93), MRK: 58.66 (+1.14), ABBV: 71.36 (+0.13)
Is Gilead Sciences About to Make an Acquisition?
ESTMZ - Mon Jul 27, 2:24PM CDT
Gilead Sciences (GILD) reports its FQ2 ’15 results after the closing bell tomorrow. Both Estimize and Wall Street are predicting a fall in EPS and revenues QoQ. Estimize are forecasting an EPS figure of $2.77 and a revenue target of $7.540B. Wall...
SPY: 210.41 (+1.08), GILD: 117.00 (+3.93), ALXN: 202.87 (-0.68), ABBV: 71.36 (+0.13), NDAQ: 51.07 (+0.43)
4 Stocks to Fight the Virus on World Hepatitis Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 12:51PM CDT
Let's turn the spotlight this World Hepatitis Day on some hepatitis-focused companies poised to grow.
ESRX: 92.20 (-0.18), GILD: 117.00 (+3.93), ACHN: 8.40 (-0.01), MRK: 58.66 (+1.14), ABBV: 71.36 (+0.13), BMY: 64.53 (-0.13), NVS: 103.82 (+1.03)
Gilead Can Soothe Biotech Investor Fears with Great 2Q Earnings
at The Street - Mon Jul 27, 11:42AM CDT
Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.
GILD: 117.00 (+3.93), ABBV: 71.36 (+0.13)
3 Signs That the Healthcare Stock Bubble Might Have Just Popped
George Budwell, The Motley Fool - Motley Fool - Mon Jul 27, 9:42AM CDT
Over the past five years or so, healthcare stocks have been absolutely trouncing the broader markets, leading many to call this unprecedented bull run a "bubble." A deeper look, though, reveals that most of this hypergrowth in the healthcare...
BIIB: 311.50 (-8.43), ILMN: 215.37 (-2.45), ABBV: 71.36 (+0.13)
Company News for July 27, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:10AM CDT
Companies in the News are: ABBV,COG,XRX,JCI
COG: 26.64 (-0.16), XRX: 10.78 (+0.12), ABBV: 71.36 (+0.13), JCI: 45.28 (+0.84)
European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elotuzumab) For the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies
Business Wire - Mon Jul 27, 6:00AM CDT
--Empliciti is poised to be the first-in-class SLAMF7-directed immunostimulatory antibody
ABBV: 71.36 (+0.13), BMY: 64.53 (-0.13)
AbbVie (ABBV) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Fri Jul 24, 2:44PM CDT
The following AbbVie (ABBV) conference call took place on July 24, 2015, 09:00 AM ET. This is a transcript of that earnings call:
ABBV: 71.36 (+0.13)
AbbVie's Investments Begin Kicking In
Todd Campbell, The Motley Fool - Motley Fool - Fri Jul 24, 2:20PM CDT
Source: AbbVie. AbbVie Inc .'s investments to offset the impact of lost sales tied to expiring patent protection on Humira in 2017 include a big push into hepatitis C and its $21 billion acquisition of the cancer drugmaker Pharmacyclics earlier...
ABBV: 71.36 (+0.13)
TECHNIVIE(TM) (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA Approval as the First and Only All-Oral, Interferon-Free Treatment for Genotype 4 Chronic Hepatitis C in the U.S.
PR Newswire - Fri Jul 24, 1:00PM CDT
AbbVie (NYSE: ABBV), a global, research-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved TECHNIVIE (ombitasvir, paritaprevir, and ritonavir tablets) in combination with ribavirin (RBV) for the treatment of adults with genotype 4 (GT4) chronic hepatitis C virus (HCV) infection who do not have cirrhosis. TECHNIVIE is the first and only all-oral, interferon-free, direct-acting antiviral treatment approved in the U.S. for adult patients with GT4 chronic HCV infection. The approval of TECHNIVIE marks an important advancement in providing this historically difficult-to-treat population of HCV patients an opportunity for a cure. Virologic cure is defined as a sustained virologic response (SVR), which is when the virus is no longer detectable in the patient's blood 12 weeks after treatment (SVR12).1 TECHNIVIE is not recommended for use in patients with moderate hepatic impairment (Child-Pugh
.
ABBV: 71.36 (+0.13)
Biogen's Big-Volume Plunge Marks End Of 5-Year Run
at Investor's Business Daily - Fri Jul 24, 12:26PM CDT
Biogen's (BIIB) second-quarter earnings topped views, but its flagship drugs Tecfidera and Tysabri both missed sales expectations. That caused the biotech's quarterly revenue growth to come in well below consensus estimates. The company also cut its...
BIIB: 311.50 (-8.43), VRX: 255.54 (-2.41), LLY: 85.15 (-0.53), ABBV: 71.36 (+0.13), BMY: 64.53 (-0.13), CELG: 133.97 (-1.45)
Biogen Plunges On Slashed Guidance; AbbVie Q2 Mixed
at Investor's Business Daily - Fri Jul 24, 10:44AM CDT
Big-cap biotech Biogen (BIIB) beat Q2 earnings estimates Friday, but it lowered its guidance and reported failure in a clinical trial, sending its stock plummeting. Meanwhile, big pharma AbbVie (ABBV) reported a steadier quarter and affirmed its...
JNJ: 99.88 (+0.86), BIIB: 311.50 (-8.43), ABBV: 71.36 (+0.13)
AbbVie (ABBV) Stock Sliding on Earnings Miss
at The Street - Fri Jul 24, 10:33AM CDT
AbbVie (ABBV) shares are tumbling after the drug maker reported weaker-than-expected fiscal 2015 second quarter earnings results.
ABBV: 71.36 (+0.13)
AbbVie Tops Earnings, Misses on Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Jul 24, 9:39AM CDT
Although AbbVie's (ABBV) second quarter earnings surpassed expectations, the revenue miss is disappointing.
NLNK: 51.00 (-2.81), LGND: 102.51 (-3.33), AMAG: 64.05 (-2.18), ABBV: 71.36 (+0.13)
AbbVie (ABBV) Tops 2Q Earnings but Misses Revenues - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 24, 8:16AM CDT
AbbVie (ABBV) Tops 2Q Earnings but Misses Revenues
ABBV: 71.36 (+0.13)
AbbVie Reports Second-Quarter 2015 Financial Results
PR Newswire Europe - Fri Jul 24, 6:58AM CDT
- Reports Second-Quarter Adjusted EPS of $1.08, Up 31.7 Percent and Exceeding Previous Guidance Range of $1.04 to $1.06 (Reports GAAP EPS of $0.83)
ABBV: 71.36 (+0.13)
AbbVie (ABBV) Stock Price Target Raised at Deutsche Bank
at The Street - 53 mins ago
AbbVie (ABBV) price target was increased to $85 from $80 at Deutsche Bank, while reiterating its 'buy' rating.
ABBV: 71.36 (+0.13)
Gilead (GILD) Beats on Q2 Earnings, Raises 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 33 mins ago
Gilead Sciences, Inc.'s (GILD) second-quarter earnings (including stock-based compensation expenses) of $3.10 per share surpassed the Zacks Consensus Estimate of $2.83.
GILD: 117.00 (+3.93), LGND: 102.51 (-3.33), ABBV: 71.36 (+0.13), ANAC: 147.03 (-4.28)
Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 338.10 (-1.40), BIIB: 311.50 (-8.43), SHPG: 267.25 (+4.00), MYL: 57.07 (+0.72), AMGN: 172.11 (-0.63), ABBV: 71.36 (+0.13), TEVA: 71.22 (-0.19)
The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts
ESRX: 92.20 (-0.18), GILD: 117.00 (+3.93), ACHN: 8.40 (-0.01), MRK: 58.66 (+1.14), ABBV: 71.36 (+0.13)
Avoid Gilead Shares for Now
at The Street - Tue Jul 28, 7:00AM CDT
Competition and lower earnings cloud its future.
GILD: 117.00 (+3.93), MRK: 58.66 (+1.14), ABBV: 71.36 (+0.13)
Is Gilead Sciences About to Make an Acquisition?
ESTMZ - Mon Jul 27, 2:24PM CDT
Gilead Sciences (GILD) reports its FQ2 ’15 results after the closing bell tomorrow. Both Estimize and Wall Street are predicting a fall in EPS and revenues QoQ. Estimize are forecasting an EPS figure of $2.77 and a revenue target of $7.540B. Wall...
SPY: 210.41 (+1.08), GILD: 117.00 (+3.93), ALXN: 202.87 (-0.68), ABBV: 71.36 (+0.13), NDAQ: 51.07 (+0.43)
4 Stocks to Fight the Virus on World Hepatitis Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 12:51PM CDT
Let's turn the spotlight this World Hepatitis Day on some hepatitis-focused companies poised to grow.
ESRX: 92.20 (-0.18), GILD: 117.00 (+3.93), ACHN: 8.40 (-0.01), MRK: 58.66 (+1.14), ABBV: 71.36 (+0.13), BMY: 64.53 (-0.13), NVS: 103.82 (+1.03)
Gilead Can Soothe Biotech Investor Fears with Great 2Q Earnings
at The Street - Mon Jul 27, 11:42AM CDT
Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.
GILD: 117.00 (+3.93), ABBV: 71.36 (+0.13)
3 Signs That the Healthcare Stock Bubble Might Have Just Popped
George Budwell, The Motley Fool - Motley Fool - Mon Jul 27, 9:42AM CDT
Over the past five years or so, healthcare stocks have been absolutely trouncing the broader markets, leading many to call this unprecedented bull run a "bubble." A deeper look, though, reveals that most of this hypergrowth in the healthcare...
BIIB: 311.50 (-8.43), ILMN: 215.37 (-2.45), ABBV: 71.36 (+0.13)
Company News for July 27, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:10AM CDT
Companies in the News are: ABBV,COG,XRX,JCI
COG: 26.64 (-0.16), XRX: 10.78 (+0.12), ABBV: 71.36 (+0.13), JCI: 45.28 (+0.84)
European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elotuzumab) For the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies
Business Wire - Mon Jul 27, 6:00AM CDT
--Empliciti is poised to be the first-in-class SLAMF7-directed immunostimulatory antibody
ABBV: 71.36 (+0.13), BMY: 64.53 (-0.13)
AbbVie (ABBV) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Fri Jul 24, 2:44PM CDT
The following AbbVie (ABBV) conference call took place on July 24, 2015, 09:00 AM ET. This is a transcript of that earnings call:
ABBV: 71.36 (+0.13)
AbbVie's Investments Begin Kicking In
Todd Campbell, The Motley Fool - Motley Fool - Fri Jul 24, 2:20PM CDT
Source: AbbVie. AbbVie Inc .'s investments to offset the impact of lost sales tied to expiring patent protection on Humira in 2017 include a big push into hepatitis C and its $21 billion acquisition of the cancer drugmaker Pharmacyclics earlier...
ABBV: 71.36 (+0.13)
TECHNIVIE(TM) (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA Approval as the First and Only All-Oral, Interferon-Free Treatment for Genotype 4 Chronic Hepatitis C in the U.S.
PR Newswire - Fri Jul 24, 1:00PM CDT
AbbVie (NYSE: ABBV), a global, research-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved TECHNIVIE (ombitasvir, paritaprevir, and ritonavir tablets) in combination with ribavirin (RBV) for the treatment of adults with genotype 4 (GT4) chronic hepatitis C virus (HCV) infection who do not have cirrhosis. TECHNIVIE is the first and only all-oral, interferon-free, direct-acting antiviral treatment approved in the U.S. for adult patients with GT4 chronic HCV infection. The approval of TECHNIVIE marks an important advancement in providing this historically difficult-to-treat population of HCV patients an opportunity for a cure. Virologic cure is defined as a sustained virologic response (SVR), which is when the virus is no longer detectable in the patient's blood 12 weeks after treatment (SVR12).1 TECHNIVIE is not recommended for use in patients with moderate hepatic impairment (Child-Pugh
. ABBV: 71.36 (+0.13)
Biogen's Big-Volume Plunge Marks End Of 5-Year Run
at Investor's Business Daily - Fri Jul 24, 12:26PM CDT
Biogen's (BIIB) second-quarter earnings topped views, but its flagship drugs Tecfidera and Tysabri both missed sales expectations. That caused the biotech's quarterly revenue growth to come in well below consensus estimates. The company also cut its...
BIIB: 311.50 (-8.43), VRX: 255.54 (-2.41), LLY: 85.15 (-0.53), ABBV: 71.36 (+0.13), BMY: 64.53 (-0.13), CELG: 133.97 (-1.45)
Biogen Plunges On Slashed Guidance; AbbVie Q2 Mixed
at Investor's Business Daily - Fri Jul 24, 10:44AM CDT
Big-cap biotech Biogen (BIIB) beat Q2 earnings estimates Friday, but it lowered its guidance and reported failure in a clinical trial, sending its stock plummeting. Meanwhile, big pharma AbbVie (ABBV) reported a steadier quarter and affirmed its...
JNJ: 99.88 (+0.86), BIIB: 311.50 (-8.43), ABBV: 71.36 (+0.13)
AbbVie (ABBV) Stock Sliding on Earnings Miss
at The Street - Fri Jul 24, 10:33AM CDT
AbbVie (ABBV) shares are tumbling after the drug maker reported weaker-than-expected fiscal 2015 second quarter earnings results.
ABBV: 71.36 (+0.13)
AbbVie Tops Earnings, Misses on Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Jul 24, 9:39AM CDT
Although AbbVie's (ABBV) second quarter earnings surpassed expectations, the revenue miss is disappointing.
NLNK: 51.00 (-2.81), LGND: 102.51 (-3.33), AMAG: 64.05 (-2.18), ABBV: 71.36 (+0.13)
AbbVie (ABBV) Tops 2Q Earnings but Misses Revenues - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 24, 8:16AM CDT
AbbVie (ABBV) Tops 2Q Earnings but Misses Revenues
ABBV: 71.36 (+0.13)
AbbVie Reports Second-Quarter 2015 Financial Results
PR Newswire Europe - Fri Jul 24, 6:58AM CDT
- Reports Second-Quarter Adjusted EPS of $1.08, Up 31.7 Percent and Exceeding Previous Guidance Range of $1.04 to $1.06 (Reports GAAP EPS of $0.83)
ABBV: 71.36 (+0.13)
